Regenerative Medicine

Regenerative Medicine is published by Future Medicine Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pluripotent Stem Cells Research, Biomedical Ethics and Regulation and Mesenchymal stem cell research, together about 44.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

Source: LetPub

Research area (LetPub): Engineering, Biomedical

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

2.95LetPub · 2026-09-13

CiteScore 2026-06

3.9LetPub · 2026-09-13

SJR 2026-06

0.49LetPub · 2026-09-13

SNIP 2026-06

0.42LetPub · 2026-09-13

h-index

53LetPub · 2026-09-13

h-index

88OpenAlex · 2026-10-01

i10-index

849OpenAlex · 2026-10-01

2-year mean citedness

1.91OpenAlex · 2026-10-01

Self-citation rate

0%LetPub · 2026-09-13

Share of gold OA articles

16.79%LetPub · 2026-09-13

Volume

Articles per year

44LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

ModerateLetPub · 2026-09-13

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

No source has fee information yet; check the journal's website.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Publisher

Future Medicine Ltd.

Country or region

ENGLAND

Language

English

Frequency

Bimonthly

Founded

2006

ISSN

1746-0751

Electronic ISSN

1746-076X

Official links

• Journal homepage ↗LetPub
• Submission system ↗LetPub